

Supplementary Table 11. Characteristics of included studies comparing two different mucoprotectives in key question #8

Studies	Comparison	No. of experiment	No. of control	Duration, wk	Outcome
Civello et al. ⁷⁹ (1988)	Sulglycotide vs. Sucralfate	25	25	6	Symptom improvement, endoscopic findings, histology
Barbara et al. ⁸⁰ (1990)	Sulglycotide vs. Sucralfate	50	39	6	Histology
Psilogen et al. ⁸¹ (1990)	Sulglycotide vs. Sucralfate	93	94	6	Symptom improvement, endoscopic findings, histology
Seol et al. ⁸² (2004)	Stillen vs. Cetraxate	186	186	2	Symptom improvement, endoscopic findings
Jeong et al. ⁸³ (2007)	Sulglycotide vs. Sucralfate	36	37	3	Symptom improvement, endoscopic findings
Du et al. ⁸⁴ (2008)	Rebamipide vs. Sucralfate	345	107	8	Symptom improvement, histology
Choi et al. ⁸⁵ (2011)	Sulglycotide vs. Teprenone	60	61	4	Symptom improvement, endoscopic findings
Du et al. ⁸⁶ (2012)	Gefarnate vs. Sucralfate	118	117	6	Symptom improvement, endoscopic findings, histology
Moon et al. ⁸⁷ (2013)	Sulglycotide vs. Rebamipide	98	99	4	Symptom improvement, endoscopic findings